Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL
Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL
Recruiting · NCT05694312 · Registry updated 2023-12-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, anemia, autoimmune disease, autoimmune hemolytic anemia, hematologic disorder, hemolytic anemia, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2023-12-01 | NCT05694312 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Gruppo Italiano Malattie EMatologiche dell'Adulto | 40 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Ematologia Osp Careggi | Florence | Italy | 1 |
| Ematologia Osp Maggiore della Carità | Novara | Italy | 1 |
| Ematologia Osp Molinette | Torino | Italy | 1 |